On February 23, 2021, BMS announced the development of a new cell therapy manufacturing facility in Devens, Mass. The new site, which will first manufacture Breyanzi, BMS’ first CAR T cell therapy recently approved by the FDA, will be completed in 2021 and ready for commercial manufacturing by 2023.
Construction of the site will add hundreds of jobs to the local economy with one million hours of work estimated to complete the site construction and certification. Once complete, BMS will hire several hundred employees for cell therapy development and manufacturing roles at the facility.
The 244,000 square foot facility will be equipped with BMS’ highly trained teams, cutting-edge, next generation technologies and a reliable manufacturing platform. The cell therapy manufacturing facility will be an extension of the company’s existing 89-acre Devens campus, which supports process development, clinical and commercial manufacturing for biologic medicines. The new site will provide additional career development opportunities for current and prospective employees in the Boston area, allowing them to gain specialized industry experience in cell therapy development and commercial cell therapy manufacturing.
The Devens campus is part of BMS’ growing presence in Massachusetts, which also includes two R&D facilities in Cambridge that BMS will be bringing together into a new facility at Cambridge Crossing in 2023.
Please see full announcement here with more information.